Scientists have developed a new drug, JRT, that retains the brain-healing abilities of LSD but without the hallucinogenic effects.
JRT promotes brain growth, boosts mental flexibility, and shows antidepressant effects without triggering hallucinations or psychosis behaviors.
In experiments with mice, JRT increased dendritic spine density by 46% and synapse numbers by 18%.
JRT targets 5-HT2A serotonin receptors to promote brain plasticity, potentially offering a safer alternative for treating conditions like schizophrenia.
Unlike LSD, JRT did not induce hallucinations or trigger gene patterns linked to schizophrenia, showing positive effects on cognitive tasks associated with the condition.
JRT passed tests for depression, displaying powerful effects and improving mental skills like flexible thinking.
The development of JRT was a lengthy process, taking nearly five years to create a molecule that offers brain benefits without hallucinogenic risks.
JRT is part of a new class of nonhallucinogenic psychoplastogens that aim to repair the brain without disrupting reality, potentially revolutionizing mental health treatment.
The drug is being further refined and studied for its effectiveness in other brain disorders like Alzheimer's and major depression.
If successful in human trials, JRT could provide relief for individuals with challenging brain conditions without compromising their reality.